NCT07568535Phase 3Not yet recruiting

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

Study sponsor: Mesoblast, Ltd. · MESO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02-28Estimated
Enrollment · participants180Estimated
Source updated2026-05-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.